Neovasc Inc. to participate in Lazard Capital Markets Annual Medical Technology and Life Sciences/Tools Snowbird Conference

TSX Venture Exchange: NVC

VANCOUVER, Feb. 22, 2012 /CNW/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today announced that the company will participate in the Lazard Capital Markets Annual Medical Technology and Life Sciences/Tools Snowbird Conference.  The event is being held at the Snowbird Resort in Snowbird, UT February 29-March 2, 2012.

The conference format consists of one-on-one meetings between participating companies and institutional investors.  Investors interested in meeting with Neovasc should contact Lazard Capital Markets directly.

About Neovasc Inc.
Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves. For more information, visit: www.neovasc.com.

Corporate contact:      
Neovasc Inc.
Chris Clark
604 248-4138

U.S. media & investor contact:
GendeLLindheim BioCom Partners
Barbara Lindheim
212 584-2276, ext. 201
[e-mail]